Radiation therapy before stem cell transplant for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of radiation therapy called automated total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant. It's designed to treat blood cancers like leukemia and myelodysplastic syndrome by destroying cancer cells and preparing the body to accept donor stem cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–60 (Cohort A) or 18–70 (Cohort B)
- Diagnosed with acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, or MDS/MPN overlap
- Have adequate heart, lung, liver, and kidney function
- This will be your first stem cell transplant (Cohort A) OR you've had a stem cell transplant before that didn't work long-term (Cohort B)
- Have a matched or partially matched donor (sibling, unrelated donor, or haploidentical relative)
- Able to use birth control if sexually active with childbearing potential
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial tests a stronger chemotherapy and radiation regimen before a donor stem cell transplant for people with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to eliminate any remaining cancer cells and improve transplant success.
This trial tests a conditioning regimen (total marrow and lymphoid irradiation, fludarabine, and melphalan) before a donor stem cell transplant for people with high-risk myelodysplastic syndrome or acute myeloid leukemia. It aims to reduce side effects while still controlling the disease.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.